(VIANEWS) – Novanta (NOVT), Eldorado Gold Corporation Ordinary Shares (EGO), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Novanta (NOVT)
24.8% sales growth and 9.36% return on equity
Novanta Inc., together with its subsidiaries, provides precision medicine and manufacturing, medical solutions, and robotics and automation solutions in the United States and internationally. The company operates through three segments: Precision Medicine and Manufacturing, Medical Solutions, and Robotics and Automation. The Precision Medicine and Manufacturing segment offers photonics-based solutions, including laser scanning, beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. The Robotics and Automation segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force and distributors under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, General Scanning, ATI Industrial Automation, Celera Motion, IMS, MicroE, Applimotion, Zettlex, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is headquartered in Bedford, Massachusetts.
Earnings Per Share
As for profitability, Novanta has a trailing twelve months EPS of $1.72.
PE Ratio
Novanta has a trailing twelve months price to earnings ratio of 106.26. Meaning, the purchaser of the share is investing $106.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.36%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 2.8%, now sitting on 899.85M for the twelve trailing months.
Sales Growth
Novanta’s sales growth is 8.6% for the current quarter and 24.8% for the next.
2. Eldorado Gold Corporation Ordinary Shares (EGO)
23.1% sales growth and 4.99% return on equity
Eldorado Gold Corporation and its subsidiaries engage in the exploration, discovery, acquisition, financing, development, production, sale, and reclamation of mineral products, primarily in Turkey, Canada, Greece, Brazil, and Romania. The company primarily produces gold, as well as silver, lead, zinc, and iron ore. It operates five mines: Kisladag and Efemcukuru located in western Turkey, Lamaque in Canada, and Olympias and Stratoni located in northern Greece. The company was formerly known as Eldorado Corporation Ltd. and changed its name to Eldorado Gold Corporation in April 1996. Eldorado Gold Corporation was founded in 1992 and is headquartered in Vancouver, Canada.
Earnings Per Share
As for profitability, Eldorado Gold Corporation Ordinary Shares has a trailing twelve months EPS of $0.88.
PE Ratio
Eldorado Gold Corporation Ordinary Shares has a trailing twelve months price to earnings ratio of 17.59. Meaning, the purchaser of the share is investing $17.59 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.99%.
3. United Therapeutics Corporation (UTHR)
18.7% sales growth and 19.25% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.76.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 14.75. Meaning, the purchaser of the share is investing $14.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.25%.
Moving Average
United Therapeutics Corporation’s worth is higher than its 50-day moving average of $317.49 and way higher than its 200-day moving average of $256.37.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 17.8% and 48.4%, respectively.
4. Bruker Corporation (BRKR)
17.8% sales growth and 22.86% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Earnings Per Share
As for profitability, Bruker Corporation has a trailing twelve months EPS of $2.39.
PE Ratio
Bruker Corporation has a trailing twelve months price to earnings ratio of 25.94. Meaning, the purchaser of the share is investing $25.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.86%.
Sales Growth
Bruker Corporation’s sales growth for the next quarter is 17.8%.
Yearly Top and Bottom Value
Bruker Corporation’s stock is valued at $62.00 at 16:22 EST, way under its 52-week high of $94.86 and way above its 52-week low of $53.79.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 3, 2024, the estimated forward annual dividend rate is 0.2 and the estimated forward annual dividend yield is 0.32%.
5. BioMarin Pharmaceutical (BMRN)
14.1% sales growth and 5.1% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $1.32.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 67.15. Meaning, the purchaser of the share is investing $67.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.1%.
Sales Growth
BioMarin Pharmaceutical’s sales growth is 15.6% for the ongoing quarter and 14.1% for the next.
Moving Average
BioMarin Pharmaceutical’s value is higher than its 50-day moving average of $83.34 and above its 200-day moving average of $86.73.
Yearly Top and Bottom Value
BioMarin Pharmaceutical’s stock is valued at $88.64 at 16:22 EST, way below its 52-week high of $99.56 and way higher than its 52-week low of $73.68.
Volume
Today’s last reported volume for BioMarin Pharmaceutical is 1364070 which is 45.5% below its average volume of 2502930.
6. Iron Mountain Incorporated (IRM)
10.6% sales growth and 81.13% return on equity
Iron Mountain Incorporated (NYSE: IRM), founded in 1951, is the global leader for storage and information management services. Trusted by more than 225,000 organizations around the world, and with a real estate network of more than 90 million square feet across more than 1,480 facilities in approximately 50 countries, Iron Mountain stores and protects billions of valued assets, including critical business information, highly sensitive data, and cultural and historical artifacts. Providing solutions that include secure records storage, information management, digital transformation, secure destruction, as well as data centers, cloud services and art storage and logistics, Iron Mountain helps customers lower cost and risk, comply with regulations, recover from disaster, and enable a more digital way of working.
Earnings Per Share
As for profitability, Iron Mountain Incorporated has a trailing twelve months EPS of $0.78.
PE Ratio
Iron Mountain Incorporated has a trailing twelve months price to earnings ratio of 137.65. Meaning, the purchaser of the share is investing $137.65 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 81.13%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13%, now sitting on 5.82B for the twelve trailing months.
Volume
Today’s last reported volume for Iron Mountain Incorporated is 1365320 which is 33.06% below its average volume of 2039750.
7. Antero Midstream Partners LP (AM)
7% sales growth and 18.14% return on equity
Antero Midstream Corporation owns and operates midstream energy assets. It owns and operates natural gas gathering pipelines, compression stations, processing and fractionation plants, and water handling and treatment assets in the Marcellus Shale and Utica Shale basins. The company was founded in 2013 and is headquartered in Denver, Colorado.
Earnings Per Share
As for profitability, Antero Midstream Partners LP has a trailing twelve months EPS of $0.8.
PE Ratio
Antero Midstream Partners LP has a trailing twelve months price to earnings ratio of 17.54. Meaning, the purchaser of the share is investing $17.54 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.14%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jul 24, 2024, the estimated forward annual dividend rate is 0.9 and the estimated forward annual dividend yield is 6.72%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 15% and 14.3%, respectively.
8. Essent Group Ltd. (ESNT)
6.3% sales growth and 14.61% return on equity
Essent Group Ltd., through its subsidiaries, provides private mortgage insurance and reinsurance for mortgages secured by residential properties located in the United States. Its mortgage insurance products include primary, pool, and master policy. The company also provides information technology maintenance and development services; customer support-related services; underwriting consulting; and contract underwriting services. It serves the originators of residential mortgage loans, such as regulated depository institutions, mortgage banks, credit unions, and other lenders. The company was founded in 2008 and is based in Hamilton, Bermuda.
Earnings Per Share
As for profitability, Essent Group Ltd. has a trailing twelve months EPS of $6.91.
PE Ratio
Essent Group Ltd. has a trailing twelve months price to earnings ratio of 8.49. Meaning, the purchaser of the share is investing $8.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.61%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 16.4%, now sitting on 1.16B for the twelve trailing months.
Yearly Top and Bottom Value
Essent Group Ltd.’s stock is valued at $58.70 at 16:22 EST, below its 52-week high of $64.05 and way higher than its 52-week low of $45.63.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Aug 30, 2024, the estimated forward annual dividend rate is 1.12 and the estimated forward annual dividend yield is 1.9%.
Moving Average
Essent Group Ltd.’s value is above its 50-day moving average of $57.93 and above its 200-day moving average of $54.16.
